IC50 values of CHIR-258 against human myeloma cell lines
Cell line . | t(4;14) . | FGFR3 genotype . | IC50, nM . |
|---|---|---|---|
| KMS11 | + | Y373C | 90 |
| KMS18 | + | G384D | 550 |
| OPM2 | + | K650E | 90 |
| H929 | + | WT | > 2500 |
| 8226 | — | ND | > 2500 |
| U266 | — | ND | > 2500 |
Cell line . | t(4;14) . | FGFR3 genotype . | IC50, nM . |
|---|---|---|---|
| KMS11 | + | Y373C | 90 |
| KMS18 | + | G384D | 550 |
| OPM2 | + | K650E | 90 |
| H929 | + | WT | > 2500 |
| 8226 | — | ND | > 2500 |
| U266 | — | ND | > 2500 |
Listed are MM cell lines and the presence (+) or absence (-) of the t(4;14) translocation and the FGFR3 mutations. The concentration of CHIR-258 that inhibits 50% viability (IC50) as compared with DMSO control (MTT assay or Cell Titer Glo) after 72 hours of incubation with CHIR-258 was determined.
WT denotes wild-type genotype; ND, not determined.